Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM98NOU)

Drug Name

Batiraxcept Drug Info

Synonyms

AVB-S6-500

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting AXL receptor tyrosine kinase ligand (GAS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AVB-500	DMORJD4	IgA nephropathy	MF8Y	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AXL receptor tyrosine kinase ligand (GAS6)	TT69QD2	GAS6_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04729608) A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). U.S.National Institutes of Health.
2	Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500. Clin Transl Sci. 2020 Jan;13(1):204-211.
3	Clinical pipeline report, company report or official report of Aravive.